Pharmacokinetic Evaluations of Tabalumab Following Subcutaneous Administration by Prefilled syringe or Auto-Injector in Patients with Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate. [Farmakokinetické hodnocení tabalumabu po podkožním podání pomocí předplněné injekční stříkačky nebo autoinjektoru u pacientů s revmatoidní artritidou, kteří měli nedostačující odezvu na metotrexát].

Trial Profile

Pharmacokinetic Evaluations of Tabalumab Following Subcutaneous Administration by Prefilled syringe or Auto-Injector in Patients with Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate. [Farmakokinetické hodnocení tabalumabu po podkožním podání pomocí předplněné injekční stříkačky nebo autoinjektoru u pacientů s revmatoidní artritidou, kteří měli nedostačující odezvu na metotrexát].

Discontinued
Phase of Trial: Phase III

Latest Information Update: 03 Apr 2014

At a glance

  • Drugs Tabalumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacokinetics; Registrational
  • Sponsors Eli Lilly
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Feb 2013 Status changed from suspended to discontinued, as reported in an Eli Lilly media release.
    • 13 Dec 2012 Status changed from recruiting to suspended, as reported in an Eli Lilly media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top